AI Science Tracker

Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

University of Oxford; Emory University · 12 Mar 2020 · medicine

Discovery

Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

Source check: Source checked. Not independent scientific confirmation.

Finding: Paired Naive Bayes models prospectively prioritized ponatinib analogs for c-Abl potency and reduced hERG liability. Of six new compounds tested, two combined sub-10 nM c-Abl activity with improved hERG assay profiles; this is biochemical optimization, not evidence of Parkinson’s efficacy or cardiac safety.

Technology: Paired Naïve Bayes networks

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
A single Naive Bayes network predicted c-Abl potency; two networks in concert prioritized c-Abl potency and predicted hERG IC50 greater than 1 μM, and the workflows were prospectively tested.
Test and result
Six novel compounds were tested. Table 1 reports compounds 4 and 5 with c-Abl IC50 below 10 nM and hERG IC50 5.02 and 12.1 μM; nilotinib/ponatinib hERG values are 0.45/0.77 μM. The correction swaps compounds 4/5 in the separate kinase-panel Table 2, not these Table 1 values.
Limitation / still unknown
The enzyme/channel and cell-toxicity assays do not establish Parkinson’s efficacy, in-vivo exposure, or clinical cardiac safety. The June 24 correction swaps compounds 4 and 5 in kinase-panel Table 2.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7153011/ · https://doi.org/10.1021/acsmedchemlett.9b00612

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 18 Nov 2026. Review scope: PMC Results and Table 1; indexed primary correction Table 2; ACS online/issue publication metadata..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.